2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Harmful

Warning

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Identifiers

IUPAC Name

(2S)-3-(4-iodophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid

InChIKey

JZLZDBGQWRBTHN-NSHDSACASA-N

SMILES

CC(C)(C)OC(=O)N[C@@H](CC1=CC=C(C=C1)I)C(=O)O

Synonyms (15)

Boc-4'-iodo-D-Phe
Boc-4'-iodo-L-Phe
Boc-Phe(4-I)-OH
Boc-pI-Phe-OH
N-Boc-4-iodophenylalanine
n-boc-4-iodo-l-phenylalanine
n-boc-p-iodo-l-phenylalanine

Sourcing this compound?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request Supplier? List your product for this CAS

(2S)-2-{[(Tert-Butoxy)Carbonyl]Amino}-3-(4-Iodophenyl)Propanoic Acid

Related Compounds

Related Reading

Safety Reference